Research graph
References from CO ‐Rebreathing in Essential Thrombocythemia and Polycythemia Vera. A Revival of an Old Methodology to Improve Diagnosis and Phlebotomy Decisions. Local targets link to admitted publications; unresolved targets remain external evidence.
Myeloproliferative Neoplasms
10.1056/nejmra1406186 · 2017 · External reference
Vascular Endothelial Cell Expression of JAK2V617F Is Sufficient to Promote a Pro‐Thrombotic State due to Increased P‐Selectin Expression
10.3324/haematol.2018.195321 · 2019 · External reference
Endothelial JAK2V617F Mutation Leads to Thrombosis, Vasculopathy, and Cardiomyopathy in a Murine Model of Myeloproliferative Neoplasm
10.1111/jth.15095 · 2020 · External reference
The Possible Role of Mutated Endothelial Cells in Myeloproliferative Neoplasms
10.3324/haematol.2021.278499 · 2021 · External reference
JAK2V617F‐Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F‐Positive Microparticles
10.4274/tjh.galenos.2021.2021.0607 · 2022 · External reference
Downregulated KLF2 in Polycythemia Vera and Essential Thrombocythemia Induces Prothrombotic Gene Expression
10.1182/bloodadvances.2022008052 · 2023 · External reference
JAK2 V617F Mutation in Endothelial Cells of Patients With Atherosclerotic Carotid Disease
2024 · External reference
Redefining Endothelial Progenitor Cells via Clonal Analysis and Hematopoietic Stem/Progenitor Cell Principals
10.1182/blood-2006-08-043471 · 2007 · External reference
The Pathobiology of Thrombosis, Microvascular Disease, and Hemorrhage in the Myeloproliferative Neoplasms
10.1182/blood.2020008109 · 2021 · External reference
JAK2 V617F Allele Burden in Polycythemia Vera: Burden of Proof
10.1182/blood.2022017697 · 2023 · External reference
Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN‐SAF TSS) in Chronic Myeloproliferative Neoplasms With Relation to Genetic Burden and Thrombosis
2024 · External reference
Prevalence and Phenotypes of JAK2 V617F and Calreticulin Mutations in a Danish General Population
10.1182/blood.2019001113 · 2019 · External reference
Early Detection of Myeloproliferative Neoplasms in a Danish General Population Study
10.1038/s41375-021-01159-8 · 2021 · External reference
The JAK2V617F and CALR Mutations and Risk of Cancer, Cardiovascular Diseases, and All‐Cause Mortality
10.1111/joim.70037 · 2026 · External reference
Clonal Hematopoiesis and Cardiovascular Diseases: Role of JAK2V617F
10.1016/j.jjcc.2022.02.001 · 2023 · External reference
Coronary Artery‐ and Aortic Valve Calcifications in Patients With Philadelphia‐Negative Myeloproliferative Neoplasms
10.1016/j.ijcard.2022.06.029 · 2022 · External reference
Crucial Role of Hematopoietic JAK2 V617F in the Development of Aortic Aneurysms
10.3324/haematol.2020.264085 · 2021 · External reference
JAK2V617F Mutation Drives Vascular Resident Macrophages Toward a Pathogenic Phenotype and Promotes Dissecting Aortic Aneurysm
10.1038/s41467-022-34469-1 · 2022 · External reference
Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population‐Based Study
10.1200/jco.2014.57.6652 · 2015 · External reference
Increased Neutrophil Extracellular Trap Formation Promotes Thrombosis in Myeloproliferative Neoplasms
10.1126/scitranslmed.aan8292 · 2018 · External reference
JAK2(V617F): Prevalence in a Large Chinese Hospital Population
10.1182/blood-2006-03-009472 · 2007 · External reference
The JAK2 V617F Somatic Mutation, Mortality and Cancer Risk in the General Population
10.3324/haematol.2010.033191 · 2011 · External reference
Diagnostic Value of JAK2 V617F Somatic Mutation for Myeloproliferative Cancer in 49 488 Individuals From the General Population
10.1111/bjh.12099 · 2013 · External reference
Arterial and Venous Thrombosis by High Platelet Count and High Hematocrit: 108 521 Individuals From the Copenhagen General Population Study
10.1111/jth.14574 · 2019 · External reference
Hemoglobin and the Risk of Cerebral Infarction: The Framingham Study
10.1161/01.str.3.4.409 · 1972 · External reference
Haematocrit, Hypertension and Risk of Stroke
10.1111/j.1365-2796.1994.tb01050.x · 1994 · External reference
Polycythemia Vera, the Hematocrit, and Blood‐Volume Physiology
10.1056/nejme1213283 · 2013 · External reference
Distinguishing Essential Thrombocythemia JAK2V617F From Polycythemia Vera: Limitations of Erythrocyte Values
10.3324/haematol.2018.213108 · 2019 · External reference
Time for Revival of the Red Blood Cell Count and Red Cell Mass in the Differential Diagnosis Between Essential Thrombocythemia and Polycythemia Vera?
10.3324/haematol.2019.229039 · 2019 · External reference
Conflating Polycythemia Vera With Essential Thrombocytosis
10.1182/bloodadvances.2025016843 · 2025 · External reference
Complications and Causes of Death in Polycythemia Vera
10.1111/j.0954-6820.1962.tb07186.x · 1962 · External reference
Polycythemia Vera: Myths, Mechanisms, and Management
10.1182/blood-2001-12-0349 · 2002 · External reference
Appropriate Management of Polycythaemia Vera With Cytoreductive Drug Therapy: European LeukemiaNet 2021 Recommendations
10.1016/s2352-3026(22)00046-1 · 2022 · External reference
Polycythemia Vera: Aspects of Its Current Diagnosis and Initial Treatment
10.1080/17474086.2023.2198698 · 2023 · External reference
Acute Leukemia and Myelodysplasia in Patients With a Philadelphia Chromosome Negative Chronic Myeloproliferative Disorder Treated With Hydroxyurea Alone or With Hydroxyurea After Busulphan
10.1002/ajh.10375 · 2003 · External reference
Long‐Term Incidence of Hematological Evolution in Three French Prospective Studies of Hydroxyurea and Pipobroman in Polycythemia Vera and Essential Thrombocythemia
10.1055/s-2006-942762 · 2006 · External reference
An Inconvenient Truth
10.1182/blood-2010-01-261412 · 2010 · External reference
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
10.1200/jco.2011.36.0792 · 2011 · External reference
Hydroxycarbamide: A User's Guide for Chronic Myeloproliferative Disorders
10.1586/era.11.10 · 2011 · External reference
Second Malignancies in Hydroxyurea and Interferon‐Treated Philadelphia‐Negative Myeloproliferative Neoplasms
10.1111/ejh.12787 · 2017 · External reference
Leukemic Transformation and Second Cancers in 3649 Patients With High‐Risk Essential Thrombocythemia in the EXELS Study
10.1016/j.leukres.2018.10.006 · 2018 · External reference
Skin Malignancies due to Anti‐Cancer Therapies
10.3390/cancers16111960 · 2024 · External reference
Association Between Ischemic Stroke and Iron‐Deficiency Anemia: A Population‐Based Study
10.1371/journal.pone.0082952 · 2013 · External reference
Recognition of Thrombotic Risk of Thrombocytosis in Iron Deficiency
10.3324/haematol.2020.270496 · 2021 · External reference
Iron Deficiency‐Induced Thrombocytosis Increases Thrombotic Tendency in Rats
10.3324/haematol.2019.245092 · 2021 · External reference
Iron Is a Modifier of the Phenotypes of JAK2‐Mutant Myeloproliferative Neoplasms
2023 · External reference
EnvIRONment Modifies Polycythemia Vera
10.1182/blood.2023020065 · 2023 · External reference
Increased Expression of HIF2α During Iron Deficiency‐Associated Megakaryocytic Differentiation
10.1111/jth.12884 · 2015 · External reference
Iron Deficiency Modifies Gene Expression Variation Induced by Augmented Hypoxia Sensing
10.1016/j.bcmd.2013.07.016 · 2014 · External reference
10.1182/blood-2024-211848
10.1182/blood-2024-211848 · External reference
Iron Supplementation for the Treatment of Chronic Heart Failure and Iron Deficiency: Systematic Review and Meta‐Analysis
10.1093/eurjhf/hfs017 · 2012 · External reference
A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea
10.1002/cncr.28441 · 2014 · External reference
Real‐World Analysis of Main Clinical Outcomes in Patients With Polycythemia Vera Treated With Ruxolitinib or Best Available Therapy After Developing Resistance/Intolerance to Hydroxyurea
10.1002/cncr.34195 · 2022 · External reference
Ruxolitinib in Patients With Polycythemia Vera Resistant and/or Intolerant to Hydroxyurea: European Observational Study
10.1111/ejh.14124 · 2024 · External reference
Ten Years of Experience With Ruxolitinib Since Approval for Polycythemia Vera: A Review of Clinical Efficacy and Safety
10.1002/cncr.35661 · 2025 · External reference
Total Hemoglobin Mass‐A New Parameter to Detect Blood Doping
10.1249/mss.0b013e3181820942 · 2008 · External reference
Relations Between Haemoglobin Mass, Cardiac Dimensions and Aerobic Capacity in Endurance Trained Cyclists
2009 · External reference
Assessment of Total Haemoglobin Mass: Can It Detect Erythropoietin‐Induced Blood Manipulations?
10.1007/s00421-009-1259-3 · 2010 · External reference
The Evolving Science of Detection of ‘Blood Doping’
10.1111/j.1476-5381.2011.01822.x · 2012 · External reference
Red Cell Volume Expansion at Altitude: A Meta‐Analysis and Monte Carlo Simulation
10.1249/mss.0b013e31829047e5 · 2013 · External reference
Altitude Training Causes Haematological Fluctuations With Relevance for the Athlete Biological Passport
10.1002/dta.1757 · 2015 · External reference
Hemoglobin Mass and Intravascular Volume Kinetics During and After Exposure to 3,454‐m Altitude
10.1152/japplphysiol.01121.2014 · 2015 · External reference
Replicate Measurements of Haemoglobin Mass During a Single Day Are Feasible and Precise
2016 · External reference
Detection of Blood Volumes and Haemoglobin Mass by Means of CO Re‐Breathing and Indocyanine Green and Sodium Fluorescein Injections
10.1080/00365513.2016.1271908 · 2017 · External reference
CORP: The Assessment of Total Hemoglobin Mass by Carbon Monoxide Rebreathing
10.1152/japplphysiol.00185.2017 · 2017 · External reference
Reproducibility of the CO Rebreathing Technique With a Lower CO Dose and a Shorter Rebreathing Duration at Sea Level and at 2320 m of Altitude
10.1080/00365513.2020.1818282 · 2020 · External reference
Relation of Unrecognized Hypervolemia in Chronic Heart Failure to Clinical Status, Hemodynamics, and Patient Outcomes
10.1016/j.amjcard.2004.01.070 · 2004 · External reference
Chronic Heart Failure Leads to an Expanded Plasma Volume and Pseudoanaemia, but Does Not Lead to a Reduction in the Body's Red Cell Volume
10.1093/eurheartj/ehn359 · 2008 · External reference
Differences in Blood Volume Components Between Hyporesponders and Responders to Erythropoietin Alfa: The Heart Failure With Preserved Ejection Fraction (HFPEF) Anaemia Trial
10.1016/j.cardfail.2013.08.508 · 2013 · External reference
True Anemia‐Red Blood Cell Volume Deficit‐In Heart Failure: A Systematic Review
10.1161/circheartfailure.116.003610 · 2017 · External reference
Red Blood Cell Volume Is Not Decreased in ESA‐Naive Anemic Chronic Kidney Disease Patients
10.14814/phy2.13900 · 2018 · External reference
Applying the Optimized CO Rebreathing Method for Measuring Blood Volumes and Hemoglobin Mass in Heart Failure Patients
10.3389/fphys.2018.01603 · 2018 · External reference
The Role of Blood Volume in Cardiac Dysfunction and Reduced Exercise Tolerance in Patients With Diabetes
10.1016/s2213-8587(19)30119-6 · 2019 · External reference
Intravascular Volumes Evaluated by a Carbon Monoxide Rebreathing Method in Patients Undergoing Chronic Hemodialysis
10.1111/hdi.12820 · 2020 · External reference
Relationship Between Plasma Volume and Essential Blood Constituents in Patients With Heart Failure and Preserved Ejection Fraction
10.1111/cpf.12614 · 2020 · External reference
Estimated Plasma Volume Status Is a Modest Predictor of True Plasma Volume Excess in Compensated Chronic Heart Failure Patients
10.1038/s41598-021-03769-9 · 2021 · External reference
Clinically Unrecognized Plasma Volume Expansion Predicts Long‐Term All‐Cause‐Mortality in Chronic Heart Failure
10.1002/clc.23893 · 2022 · External reference
Application of the Optimized CO‐Rebreathing Method for Determination of Haemoglobin Mass in Patients With Polycythemia Vera
10.1007/s00277-014-2020-5 · 2014 · External reference
Carbon Monoxide Rebreathing Method Is a Reliable Test to Evaluate the Red Cell Mass in Polycythaemia
10.1111/bjh.19169 · 2024 · External reference
Validation of a Clinically Applicable Device for Fast and Accurate Quantification of Blood Volume
10.1002/jcla.24928 · 2023 · External reference
Measurement of Red Cell, Plasma and Blood Volume: Essential Components of Diagnostic and Research Studies of Oxygen Transport
10.1016/j.bcmd.2023.102819 · 2024 · External reference
Measurement of Red Cell, Plasma, and Blood Volume: A Perspective
10.1002/ajh.27158 · 2024 · External reference
Increased Blood Reactive Oxygen Species and Hepcidin in Obstructive Sleep Apnea Precludes Expected Erythrocytosis
10.1002/ajh.26992 · 2023 · External reference
Determinants and Reference Values for Blood Volume and Total Hemoglobin Mass in Women and Men
10.1002/ajh.27162 · 2024 · External reference
CHIP‐Clinic as the Catalyst of Preventive Medicine
10.3389/frhem.2024.1459154 · 2024 · External reference
Clonal Hematopoiesis From a Diagnostic Perspective: 10 Years of CHIP
10.1007/s40291-024-00737-7 · 2024 · External reference
Burden of Phlebotomy in Patients With Polycythemia Vera in the United States: Baseline Data From the REVEAL Study [Conference Abstract]
10.1182/blood.v126.23.5187.5187 · 2015 · External reference
Ruxolitinib‐Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations
10.3390/cancers12113132 · 2020 · External reference
A Safety Evaluation of Ruxolitinib for the Treatment of Polycythemia Vera
10.1080/14740338.2023.2299391 · 2024 · External reference
Efficacy and Safety of Ruxolitinib vs Best Available Therapy for Polycythemia Vera: An Updated Systematic Review and Meta‐Analysis
10.1111/apm.13472 · 2024 · External reference
Data‐Driven Analysis of the Kinetics of the JAK2V617F Allele Burden and Blood Cell Counts During Hydroxyurea Treatment of Patients With Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis
10.1111/ejh.13700 · 2021 · External reference
A Novel Integrated Biomarker Index for the Assessment of Hematological Responses in MPNs During Treatment With Hydroxyurea and Interferon‐alpha2
10.1002/cam4.5285 · 2023 · External reference
Loss of Life Expectancy in Patients With Myeloproliferative Neoplasms in Sweden
2026 · External reference
